MedTrace Logo

PanDox: Targeted Doxorubicin in Pancreatic Tumours

NCT04852367 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-04-12

No results posted yet for this study

Summary

This study will combine focused ultrasound to generate heat, and a heat-sensitive chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug Doxorubicin given into the blood without the addition of ultrasound. We aim to determine whether the novel approach to delivering chemotherapy with heating the tumour by focused ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be measured by analysing a biopsy sample of treated tumour.

Conditions

Interventions

DEVICE

Focused Ultrasound

Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release

DRUG

Doxorubicin

Doxorubicin infusion

DRUG

ThermoDox

ThermoDox infusion

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Imunon

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Mark Middleton · Consultant Medical Oncologist and Professor of Experimental Cancer Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04852367 on ClinicalTrials.gov